CD276 and breast cancer: This relationship warrants further investigation, particularly in light of evidence from other tumor types, such as breast cancer, where high B7-H3 expression coupled with low PD-L1 levels characterizes “armored-cold” tumors, which exhibit the lowest response rates to various therapies [48].